FDA Elevates AI Device and Surgical Robot Guidance for FY2027

The U.S. Food and Drug Administration published its fiscal 2027 guidance priorities on Thursday, 1 October 2026, and MedTech Dive reports that finalizing marketing-submission and lifecycle-management guidance for AI-enabled devices sits on the agency’s A-list alongside a new draft on generative AI conversational devices for mental disorders. The same package elevates finalization of premarket guidance for robotically assisted surgical devices, a draft the agency published the prior week with comments due by 24 November, while stakeholders may comment on the priority list itself through 30 November.

Which AI documents moved to the front of the queue

In January 2025 the FDA issued draft guidance on lifecycle management for AI-enabled devices; last year’s priority exercise treated finalizing that draft as a second-tier goal, MedTech Dive’s Nick Paul Taylor writes. This year it climbs into the top finalization set covering marketing submissions and lifecycle management for AI-enabled devices. Separately, the agency plans to draft evidentiary recommendations for generative AI-enabled conversational devices aimed at mental disorders—a topic absent from last year’s list but aligned with the FDA’s August discussion paper seeking feedback on regulating generative AI-enabled medical devices.

That discussion paper, which PromptCrates previously covered in FDA’s GenAI medical-device feedback push, asked for comments through 19 October 2026 on risk assessment, competency-style premarket evaluation, and postmarket monitoring. The FY2027 draft priority on conversational mental-health devices turns that exploratory paper into a concrete guidance workstream. Developers building therapy chatbots or companion agents that meet the device definition should treat the comment windows as one continuum: influence the discussion paper now, then watch the evidentiary draft when it appears.

Surgical robots and the rest of the A-list

Robotically assisted surgical devices are not generative AI, but they share the FDA’s broader software-heavy device agenda. The recently published draft guidance covers nonclinical testing, clinical data, and labeling recommendations; the agency aims to finalize within a year of the draft, MedTech Dive reports, and is accepting feedback until 24 November. Other A-list finalization targets include air-purifying respirators, menstrual product testing and labeling, quality management systems, and the accreditation scheme for conformity assessment, plus a holdover on predetermined change control plans for medical devices. One prior-year priority on validating certain in vitro diagnostics dropped off the coming year’s list.

Second-tier, or B-list, priorities include finalizing pulse-oximeter guidance that addresses nonclinical and clinical performance testing, labeling, and premarket submissions—work that continues the agency’s focus on skin-pigmentation accuracy after a January 2025 draft. For AI sponsors, the B-list still matters as a signal of bandwidth: resources that go to pulse oximeters and respirators are resources not infinitely available for GenAI mental-health drafts. Companies should plan comment strategies around the stated dates rather than assuming AI topics will always jump the queue.

What device makers should do before November

Calendar discipline is the immediate takeaway. Comment on the surgical-robot draft by 24 November, on the priority list by 30 November, and on the August GenAI discussion paper by 19 October if that docket is still open. Sponsors of adaptive AI devices should map their change-control plans against the still-pending PCCP final guidance so they are not surprised when predetermined updates become a clearance bottleneck. Conversational mental-health product teams should start assembling evidence packages that look more like competency evaluations—benchmarks plus clinical confirmation—than like static input-output test matrices, because that is the direction the August paper sketched and the FY2027 draft priority is likely to operationalize.

None of these documents is law yet. Priority lists describe intent, not binding timelines, and MedTech Dive notes the FDA also maintains lists of guidances it will publish only if resources permit. Still, when AI lifecycle finalization and a brand-new GenAI mental-health draft both sit on the A-list in the same year, the agency is telling industry that generative features inside medical devices are leaving the white-paper phase. Adjacent clinical AI stories on PromptCrates, including Everlywell’s nationwide Clairity breast-risk tool, show how quickly authorized AI can move into consumer channels once the regulatory path clarifies; FY2027 guidance is how that path gets written for the next wave.

International alignment is the next shoe. European and UK device regulators are also writing GenAI expectations, and global sponsors hate maintaining three evidence packages for one chatbot. If the FDA’s mental-health conversational draft converges with competency-style ideas from the August paper, companies may find a template they can reuse abroad; if it diverges into U.S.-only clinical endpoints, launch sequencing will fragment. Trade associations commenting by 30 November should flag interoperability of evidence, not only domestic timelines.

Hospital health systems sit on the demand side of the same guidance. They need clearer postmarket monitoring expectations before they let GenAI mental-health tools touch patient portals at scale, especially after years of chatbot hallucination headlines. The FY2027 priorities will not answer every purchase question, but they tell CIOs which FDA documents to track in diligence checklists. Waiting for final text before even reading the drafts is how health systems get surprised by competitors who already structured their evidence the way reviewers will ask.

Primary reporting for this article: Nick Paul Taylor’s 2 October 2026 MedTech Dive coverage of the FDA’s FY2027 guidance priorities, including the AI lifecycle finalization goal, the new GenAI mental-disorder conversational-device draft, surgical-robot finalization plans, comment deadlines, and B-list pulse-oximeter work.

• MedTech Dive: FDA FY2027 AI and surgical robot guidance
• PromptCrates: FDA GenAI medical devices discussion
• PromptCrates: Everlywell Clairity breast cancer risk